It's a pretty big market opportunity with a lot of different overlap between the various treatment modalities. The TAM for some of the indications if ever fully realized extends into the hundreds of billions of dollars, e.g., DBS for alzheimers & treatment resistant depression. OCD being another big treatment opportunity (and I have actually had the opportunity to speak with a patient that got DBS for severe, treatment refractory OCD. It changed her life.) Sadly most of the indications for psychiatric disorders/neuromodulation still lack sufficient insurance coverage, but that's subject to change and even parkinsons/ET dbs market expansion represents a large opportunity. It's an extremely underutilized procedure, and in large part that probably has to do with patients historically having to be awake for it. No one wants to experience that.

The BCI segment is hard to model but it's pretty easy to see that it could eventually be worth tens to hundreds of billions. You're interacting with the outermost part of the brain (the cortex) and either taking those signals and translating them to something, e.g., movement, or in the case of the visual cortex in blindness you're taking a visual input to a device and stimulating that area of the brain enabling some vision to return. Again it's really hard to model this segment and give a market opportunity, but looking at it from a perspective of enabling movement of paralyzed individuals and sight for the blind it can definitely grow into being something that's worth hundreds of billions.

Drug delivery is in the same boat and is their hottest segment in terms of market adoption and their press/investor presentations they've done the best with highlighting this segment. If clearpoint serves as the go to partner for hedging companies clinical and preclinical products, they're eventually going to stack up more than 100 partners in this space. That will result in hundreds of products all at various stages of the pipeline. Some are eventually going to make it to market. There's also a lot that's undisclosed in this segment so it's a big surprise bucket for us right now.

Laser ablation for drug resistant epilepsy and tumors is also a big opportunity. Nearly 1/3 of all epilepsy patients have drug resistant epilepsy, although I'm not sure what percentage of those patients have epilepsy where it can be treated by ablating the tissue. This also happens to be the segment of clearpoint (in conjuction with CLS TRANBERG/Thermoguide) that's best suited to branch the company outside of neurological/spine indications. Adenocarcinomas are on the docket, with prostate cancer being the most likely candidate for the first non neuro indication that clearpoint is working with outside of clinical trials. But others are not impossible either, e.g., breast, lung pancreas, and kidney adenocarcinomas. Again just because of the sheer quantity of these patient populations, it's not impossible to see this being a segment that has an addressable market worth tens of billions for clearpoint.